Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and
pulmonary embolism (PE), is the third most common cause of vascular death after heart …

Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …

Utilizing neutrophils (NEs) to target and deliver nanodrugs to inflammation sites has
received considerable attention. NEs are involved in the formation and development of …

The incidence of pediatric venous thromboembolic disease is increasing in hospitalized
children. While the mainstay of treatment of pediatric thrombosis is anticoagulation, reports …

Thrombotic diseases have a high rate of mortality and disability, and pose a serious threat to
global public health. Currently, most thrombolytic drugs especially protein drugs have a …

Thrombotic diseases cause significant risks of disability and death worldwide. However,
conventional thrombolytic drugs have short half-lives, poor targeting capabilities, limited …

Background Recently emerged reports indicated that patients with coronavirus disease
2019 (COVID-19) might experience novo genitourinary symptoms after discharge …

В книге рассмотрены основные положения физиологии системы гемостаза и
диагностики ее нарушений, дана характеристика фармакологических препаратов …

Objective To explore disagreements in multiple systematic reviews (SRs) assessing the
benefit-to-harm ratio of thrombolytic therapy in patients with intermediate-risk pulmonary …